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Abstract
Low-grade intestinal inflammation plays a key role in 
the pathophysiology of irritable bowel syndrome (IBS), 
and this role is likely to be multifactorial. The aim of this 
review was to summarize the evidence on the spectrum 
of mucosal inflammation in IBS, highlighting the 
relationship of this inflammation to the pathophysiology 
of IBS and its connection to clinical practice. We carried 
out a bibliographic search in Medline and the Cochrane 
Library for the period of January 1966 to December 
2014, focusing on publications describing an interaction 
between inflammation and IBS. Several evidences 
demonstrate microscopic and molecular abnormalities 
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TOPIC HIGHLIGHT
Inflammation in irritable bowel syndrome: Myth or new 
treatment target?
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in IBS patients. Understanding the mechanisms 
underlying low-grade inflammation in IBS may help to 
design clinical trials to test the efficacy and safety of 
drugs that target this pathophysiologic mechanism.
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Core tip: Low-grade intestinal inflammation plays 
a key role in the pathophysiology of irritable bowel 
syndrome, and this influence is likely multifactorial. 
Several evidences showed microscopic and molecular 
abnormalities in large subsets of patients with irritable 
bowel syndrome. Understanding the mechanisms 
underlying the low-grade inflammation in this disease 
may help to design clinical trials to test the efficacy 
and safety of drugs that target this pathophysiologic 
mechanism.
Sinagra E, Pompei G, Tomasello G, Cappello F, Morreale GC, 
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INTRODUCTION
Irritable bowel syndrome (IBS) is a chronic, relapsing, 
and remitting functional disorder of the gastrointestinal 
tract characterized by abdominal pain, bloating, and 
changes in bowel habits that lack a known structural 
or anatomic explanation[1].
IBS consists of a set of altered bowel habits over 
a period of time and includes abdominal pain and 
discomfort. IBS is one of the most common diagnoses 
in primary care, accounting for approximately 12% 
of all visits[2]. In addition, a survey conducted by 
Russo et al[3] found IBS to be the most common 
functional gastrointestinal diagnosis, comprising 35% 
of all outpatient referrals to gastroenterologists[2,3]. 
Therefore, IBS is also the most common diagnosis 
for gastroenterologists, accounting for 20%-50% of 
patient visits[2,4].
With regard to the sex-related prevalence of IBS, 
in Western countries, the prevalence of IBS in female 
patients outnumbers that in male patients by 2:1[5,6]. 
Furthermore, the ratio of female to male IBS sufferers 
in the non-patient population is 2:1, and within the 
patient population who seek consultations with primary 
care physicians, females outnumber male patients by 
3:1[5,7]. Finally, in tertiary-care settings, the number of 
female IBS patients is four- to five-times higher than 
the number of males[5-8]. This prevalence should not 
only be strictly attributed to sex, but also to gender-
related differences in healthcare-seeking behavior 
and sociocultural characteristics that vary between 
men and women with IBS as well as among different 
cultures[5,6]. 
According to the Rome Ⅲ criteria, IBS is defined 
based on the presence of recurrent abdominal pain 
or discomfort at least three days per month in the 
past three months associated with two or more of the 
following: (1) improvement with defecation; (2) onset 
associated with a change in frequency of stool; and (3) 
onset associated with a change in form (appearance) 
of stool. These criteria should be fulfilled for the 
previous three months with symptom onset at least six 
months before diagnosis[9].
Rome Ⅲ criteria subtype IBS according to the 
predominant bowel habit as IBS with constipation 
(IBS-C), IBS with diarrhea (IBS-D), mixed type, and 
unclassified[9]. To this end, the definition of bowel-
habit type is based on the patient’s description of the 
stool form by referring to the Bristol Stool Scale[10]. 
Furthermore, IBS patients can be divided into two 
categories: sporadic (nonspecific) and postinfectious 
(PI-IBS) inflammatory bowel disease-associated[11,12].
IBS symptoms cannot be explained by structural 
abnormalities, and specific laboratory tests or bio-
markers are not available for IBS. Therefore, IBS is 
classified as a functional disorder whose diagnosis 
depends on the history of manifested symptoms[13].
The cause of IBS is unknown, but a single factor is 
not likely to be responsible for the several presentations 
of this complex disorder[1]; new fields of research in this 
area include mucosal inflammation, postinfectious low-
grade inflammation, genetic and immunologic factors, 
alteration of the human microbiota, alterations of the 
intestinal permeability, and dietary and neuroendocrine 
factors[13]. Usually, routine histologic examinations do 
not show significant colonic mucosal abnormalities 
in the majority of IBS patients; however, recent 
quantitative histologic, immunohistochemical, and 
ultrastructural analyses have indicated subtle organic 
alterations in these patients. 
This literature review aims to summarize the findings 
relating the spectrum of mucosal inflammation to IBS, 
highlighting their relationship to the pathophysiology of 
IBS and their connections, if any, to clinical practice.
RESEARCH
We carried out a bibliographic search in MEDLINE for 
the period of January 1966 to July 2015, and focused 
on identifying publications describing an interaction 
between inflammation and IBS. The keywords used 
were: irritable bowel syndrome, inflammation, mucosal 
inflammation, pathology, mast cells, neuroendocrine 
cells, immune cells, intestinal permeability, and enteric 
nerves. The inclusion criteria to select articles were 
based on design (systematic reviews, meta-analysis, 
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clinical trials, and experimental studies on animals) 
and population (adult patients > 18 years of age). We 
excluded articles not pertinent to this topic.
According to the aforementioned criteria, we found 
305 studies, and we excluded 100 studies because 
they were not pertinent to this topic (Figure 1).
ROLE OF ENDOSCOPY IN IBS
According to the American Gastroenterology Association, 
“a colonoscopy is recommended for patients over 
age 50 years (due to higher pretest probability of 
colon cancer), but in younger patients, performing a 
colonoscopy or sigmoidoscopy is determined by clinical 
features suggestive of disease (e.g., diarrhea, weight 
loss), and may not be indicated”[14].
However, the British guidelines suggest that, “given 
the high frequency of colonic cancer in the population 
at large, an examination of the colon is advisable 
for a change in bowel habit over the age of 50”; the 
authors of these guidelines highlighted that, “as IBS 
patients have no increased risk of colon cancer, advice 
on screening for this is no different from the general 
population”[15].
More recently, Japanese guidelines suggested 
that “colonoscopy has a diagnostic value, not only for 
excluding organic diseases but also for supporting the 
existence of pathophysiology compatible to IBS due 
to visceral hypersensitivity to colonoscopic procedures 
and colonic spasms”[16].
A prospective, multicenter study performed by 
Ishihara and coworkers[17] aimed to determine the 
presence of organic colonic lesions in IBS patients. 
Their study showed that the prevalence of organic 
colonic diseases in IBS patients was at an acceptably 
low level, thus showing that the Rome Ⅲ criteria 
are specific for the diagnosis of IBS. Conversely, 
another study performed by Hsiao and coworkers[18] 
demonstrated that IBS was not associated with the 
development of colon cancer in Taiwan.
Despite these recommendations, a recent Korean 
survey indicated that colonoscopy was the most 
commonly required test (79.5%) in IBS patients[19], 
whereas a study performed by Lieberman and 
coworkers[20] to evaluate trends in the utilization and 
outcomes of colonoscopy in the United States from 
2000 to 2011 showed that the most common reason 
for colonoscopy in patients aged < 50 years was 
the evaluation of symptoms, such as IBS (28.7%), 
together with bleeding or anemia (35.3%).
Based on these updated data, IBS still represents the 
majority of colonoscopic biopsies seen by pathologists[21] 
that are usually considered either normal or near to 
normal on routine histologic examination. These findings 
provide valuable information to the physician who is 
suspecting a diagnosis of IBS. However, the pathologists 
must be aware of variations in normal tissue as well 
as artifacts that may result from bowel preparations 
or the biopsy procedure in order to not to report these 
variations as abnormal. Furthermore, the pathologists 
must consider subtle morphologic changes reported in 
the intestinal mucosa in IBS and associated with chronic 
inflammatory cells, mast cells, enteroendocrine cells, 
and enteric nerves[22].
INFLAMMATION IN IBS
The intestinal mucosa harbors a florid immune system 
that can be regarded as “physiologically inflamed”[23]. 
Thus low-grade inflammation can only be evaluated 
using quantitative assessments[24]. IBS patients have 
been shown to exhibit significant increases in lamina 
propria immune cells in the colonic mucosa compared 
with healthy subjects, which appears to be more 
predominant in the right than in the left colon[25].
Granulocytes and plasma cells 
More than ten years ago, O’Sullivan et al[26] evaluated 
the number of plasma cells, lymphocytes, eosinophils, 
neutrophils, and macrophages in a case-control study. 
Specifically, each cell type was semiquantitatively 
graded in hematoxylin-and-eosin-stained sections of 
the entire colon, and possible increases in the number 
of mast cells (MCs) in the colon of IBS patients 
compared with controls were examined using a 
monoclonal mouse antibody for human MC tryptase 
(AA1). Other than MCs, increases in cellular infiltrate 
were not observed in the IBS group, and the number 
of MCs was significantly increased in the cecum of IBS 
patients compared with controls.
Similarly, in 2008, Piche and coworkers[27] aimed to 
examine associations between fatigue, depression, and 
the MCs of the colonic mucosa in IBS by comparing the 
numbers of CD3-positive intraepithelial T lymphocytes, 
MCs, plasma cells, eosinophils, and neutrophils in cecal 
biopsies taken during colonoscopy. There was not a 
significant difference in the numbers of intraepithelial 
lymphocytes, plasma cells, eosinophils, or neutrophils 
between IBS patients and healthy controls, but the MC 
numbers per high-power field were significantly higher 
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Figure 1  Literature findings on the relationship between irritable bowel 
syndrome and inflammation (n = 305).
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in IBS patients in the rectum[35,36], rectosigmoid 
colon[37,38], descending colon[39-44], ascending colon[36], 
cecum[45], terminal ileum[25,36,46], jejunum[47-49], and 
duodenum[29,50] (Figure 2).
However, discrepancies in data obtained from 
these studies could be due to sex-specific differences, 
bowel preparation artifacts, fixation protocols, tissue 
orientation, sample size, or IBS-related recruitment 
criteria[32,43,44,51]. Furthermore, clinical studies have also 
yielded conflicting evidence correlating MC numbers 
with the onset of abdominal pain[32].
The number of functionally active MCs (exhibiting 
changes in the release of tryptase and histamine), 
rather than the absolute number of MCs, plays a 
pivotal role in IBS[43,50]. Consequently, the role of MCs 
in IBS may be affected by cells that are functionally 
active and form close connections with enteric and 
extrinsic nerve terminals, thus determining visceral 
hypersensitivity and altered gut function[47].
Lymphocytes 
The aforementioned inflammatory changes described 
in the mucosa of IBS patients show that immune 
activation may play a role in IBS pathophysiology[34]. 
Mucosal T- and B-type lymphocytes are also part of 
the gut adaptive immune response to pathogens[32]. 
An increased density of T lymphocytes in the 
mucosa of IBS patients has been widely demonstrated. 
Specifically, the T-cell density is higher in the 
rectum[35,36,52], rectosigmoid colon[53], colon[38,48,54], 
cecum[26], jejunum[55], and duodenum[56]. Like for MCs, 
several studies showed that IBS patients exhibit a 
normal lymphocyte density in different intestinal tissue 
segments[19,36,38,53,57-61]. These discrepancies may be 
due to differences in the immunostaining techniques, 
quantification methods, and IBS-related recruitment 
criteria (Figure 3)[32].
Conversely, the density of B-cells in the rectum[19,36], 
colon[19,43,53,62], cecum[19,20], ileum[36], or jejunum[60] 
did not differ in IBS patients. However, Forshammar 
and coworkers[62] and others[32] found a decrease in 
secretory B cells in the colon (Figure 4).
in IBS patients than in healthy controls (9.3 vs 4.0, P 
= 0.001). Furthermore, the number of MCs correlated 
with the severity of fatigue and depression scores in 
IBS patients but not in healthy controls[28].
With regard to the small bowel, Walker et al[29] 
examined the MC, eosinophil, and intraepithelial 
lymphocyte populations in duodenal biopsies of 
subjects with IBS and functional dyspepsia. Their 
study showed a significant increase in the number 
of intraepithelial lymphocytes in biopsies from the 
duodenum in patients with IBS-C. However, this 
increase was not observed in the second part of the 
duodenum. Nevertheless, MC counts were also higher 
in IBS cases in both the first and second parts of the 
duodenum, but this difference was only significant for 
constipation-predominant IBS[28]. Interestingly, the 
eosinophil counts in this study did not differ between 
IBS patients and controls in either the first or second 
part of the duodenum[28].
To date, a significant difference in the numbers 
of plasma cells, neutrophils, or eosinophils has not 
been demonstrated among IBS cases[28]. Importantly, 
increases in eosinophils were not identified in IBS, 
but the eosinophil counts were elevated in individuals 
with functional dyspepsia[29]. Functional dyspepsia 
and IBS demonstrate significant overlap in cross-
sectional surveys[30], despite attempts to classify them 
separately, and a biomarker to predict the presence of 
IBS remains elusive[31]. Therefore, this histopathologic 
marker may serve to distinguish the two conditions[28].
MCs
MCs are innate immune cells involved in food allergies, 
wound healing, and protection against pathogens[32]. 
Their functional activation consists of a degranulation 
process, leading to the release of various compounds, 
such as histamine, tryptase, and chymase[32].
More than 40 years ago, Hiatt and Katz[33] were 
the first to demonstrate MC infiltration in the muscular 
layer of full-thickness colonic biopsy samples from 
four patients with “spastic colitis”[34]. Increases in 
the number of mucosal MCs have been observed 
Figure 2  Immunohistochemistry for tryptase showing increases in the number of mast cells in the colonic mucosa in inflammatory bowel disease. A: 
Irritable bowel syndrome patient; B: Control (× 40 magnification). Courtesy of Giancarlo Pompei, personal data.
A B
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With regard to intraepithelial lymphocytes, several 
discrepancies have been reported in studies assessing the 
density of these cells in IBS patients. An increase in density 
has been demonstrated in the rectum[35,36,57], colon[57], 
jejunum[55,49], and duodenum[56], but these increases were 
not confirmed by other groups[20,32,45,49,59,61].
Dendritic cells and macrophages 
Dendritic cells are antigen-presenting cells that are 
usually located at the surveillance interfaces of the 
human body, such as the skin or mucosa, and play a 
pivotal role in the generation and regulation of immune 
responses[63]. In fact, they represent the link between 
allergen uptake and the clinical manifestations of 
intestinal inflammation[64,65]. Furthermore, the gut 
also harbors abundant macrophages. These cells 
do not function as typical antigen-presenting cells 
and lack the cellular machinery for the production of 
pro-inflammatory cytokines and induction of potent 
adaptive immune responses. However, they show very 
potent phagocytic activity[65].
In a Trichinella spiralis mouse model of PI-IBS, 
Long and coworkers[66] reported numerical and 
phenotypic alterations in the lamina propria dendritic 
cells following acute T. spiralis infection. In their study, 
the lamina propria dendritic cells expressed increased 
levels of costimulatory molecules and exhibited a 
greater ability to migrate and induce CD4+ T-cell 
proliferation[66]. Consequently, these changes favored 
increased levels of pro-inflammatory interferon-γ, 
interleukin-23, and tumor necrosis factor-α production 
in the so-called “PI-IBS stage”[66,67].
With regard to macrophages, the numbers of 
resident CD68+ macrophages are reduced in PI-
IBS cases following Campylobacter jejuni infection, 
probably due to the cytotoxic nature of the pathogen 
inside host cells[50]. Similarly, Shigella spp.[68,69] and 
Salmonella infections have also been shown to be 
involved in PI-IBS, and both of these organisms are 
intracellular pathogens that induce phagocytosis by 
macrophages[70,71]. Furthermore, Salmonella seems 
to be less cytotoxic to macrophages[72] and also 
causes a marked interleukin-18 response[72] with 
important implications in exerting paracrine effects 
on surrounding immune cells (inducing interferon-γ 
expression). These changes result in increased levels 
of activated T cells in the infected intestine[47,52,54,55,57].
Enteroendocrine cells
Enteroendocrine cells (residing among the epithelial 
Figure 3  Immunohistochemistry for CD3 showing increase in the number of intraepithelial T-lymphocytes in the large bowel in inflammatory bowel 
disease. A: Irritable bowel syndrome patient; B: Normal distribution of T-lymphocytes, which are mainly distributed within the lamina propria of the large bowel of a 
control patient (× 20 magnification). Courtesy of Giancarlo Pompei, personal data.
A B
A B
Figure 4  Immunohistochemical staining for CD20. An equivalent distribution of B lymphocytes in the lamina propria was seen in the large intestine. A: Patient with 
irritable bowel syndrome; B: Control patient (× 20 magnification). Courtesy of Giancarlo Pompei, personal data.
Sinagra E et al . Inflammation in IBS
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cells of the mucosa in all gut segments, with the 
exception of the esophagus) secrete multiple 
regulatory molecules that control several functions, 
such as postprandial secretion and motility[12,73,74]. 
Animal experimental studies have demonstrated 
abnormalities in the function of enteroendocrine 
cells in the setting of gastrointestinal infection[73]. 
Enteroendocrine cells seem to be involved in visceral 
hypersensitivity, disturbed gastrointestinal motility, 
and abnormal gut secretion[12] that patients with IBS 
usually present[75-77].
In fact, visceral hypersensitivity has been shown 
in the colon of IBS patients[78-85], but the correlation 
of this disturbance with the severity of abdominal 
pain is currently poorly understood[12]. Some 
authors hypothesize the involvement of a peripheral 
mechanism in visceral hypersensitivity in IBS[86-88]. 
Because the gut mucosa can produce high levels 
of serotonin[88], a reduction in serotonin impairs 
intracellular uptake and degradation in the gut 
epithelial cells and consequently increases serotonin 
availability of in the gut mucosa[89-92]. Therefore, 
the amount of serotonin available at its receptors is 
markedly increased[12,87,88]. Due to this mechanism, 
the development of visceral hypersensitivity in PI-IBS 
patients may be due to the increase in serotonin at 
the 5-hydroxytryptamine 3 receptors of the sensory 
neurons of the enteric nervous system.
Dysmotility has also been shown in the small 
and large bowel of IBS patients, as evidenced by 
the involvement of cholecystokinin, ghrelin, secretin, 
serotonin, and peptide YY[12]. Both esophageal 
motility abnormalities and abnormal gastric emptying 
have been observed in IBS patients with conflicting 
results[93-108]. Specifically, IBS-C patients exhibit 
delayed gastric emptying, whereas accelerated 
gastric emptying was observed in IBS-D patients[77,98]. 
In this setting, ghrelin was shown to stimulate 
gastric and small- and large-bowel motility[106-117]. 
Conversely, serotonin relaxes the stomach through 
a nitrergic pathway and consequently delays gastric 
emptying[118-120]. Moreover, cholecystokinin[121-123] 
and secretin[124,125] were shown to relax the proximal 
stomach, which inhibited gastric emptying in a manner 
similar to secretin; furthermore, small-bowel transit 
was also found to be delayed overall in IBS-C patients 
and accelerated in IBS-D patients[126-131], but conflicting 
results have been reported[132-139]. 
Ghrelin, which is involved in the stimulation of 
small-bowel motility, and peptide YY, a regulator of 
the ileal brakes[140-145], play pivotal roles in gastric 
emptying by stimulating the absorption of water 
and electrolytes and inhibiting prostaglandin E2 and 
vasoactive intestinal polypeptide[146-148]. Therefore, 
ghrelin cell density is reportedly low in the stomach, 
and that of peptide YY is reported to be high in the 
ileal mucosa of IBS-C patients, whereas the ghrelin cell 
density is reported to be high in the stomach, and that 
of secretin is reported to be low in the duodenum of 
IBS-D patients[12]. Furthermore, colorectal transit was 
found to be delayed in IBS-C patients and accelerated 
in IBS-D patients[80,125,126,149-154], but contradictory 
results have been reported[12,105,152,154-176].
Finally, abnormal gastrointestinal secretion is 
common in IBS patients. Among the abnormalities 
in the enteroendocrine cells in IBS patients, low 
levels of duodenal cholecystokinin (which stimulates 
the secretion of digestive enzymes from pancreatic 
exocrine glands) and secretin (which stimulates 
pancreatic bicarbonate and fluid secretions)[122,123], as 
well as high levels of ileal peptide YY (which stimulates 
the absorption of water and electrolytes), were 
reported in IBS-C patients[12].
Intestinal permeability 
The term “mucosal barrier” was adopted by Cummings 
et al[177] in 2004 to describe “the complex structure 
that separates the internal milieu from the luminal 
environment, consisting of the vascular endothelium, 
the epithelial cell lining, and the mucus layer, next to 
which digestive secretions, immune molecules, cell 
products such as cytokines, inflammatory mediators, 
and antimicrobial peptides, are found, mainly produced 
by Paneth cells in the crypts of the small intestine”[177,178].
Conversely, impaired intestinal permeability is 
defined as “an altered permeability being nontransiently 
changed compared to the normal permeability 
leading to a loss of intestinal homeostasis, functional 
impairments and disease”[178]. Increases in the numbers 
of MCs in the gut of IBS patients were found to be 
related to changes in gut permeability[32,179-181]. In 
IBS patients, the assessment of permeability via the 
urinary recovery of orally administered markers has 
demonstrated increases in the permeability of the small 
and in the large bowels[45,182-184], but results have been 
contradictory[185-187]. Furthermore, rectal permeability 
was also reportedly increased in IBS-D patients 
following exposure to MC tryptase[188]. Finally, recent 
studies of the permeability of the epithelial barrier have 
reported a decrease in the colonic expression of the 
tight junction proteins occludin, claudin-1, and zonula 
occludens-1 in IBS patients[42,189] (Figure 5).
Several aliments, as well as microbiota and 
bile acids, have been proposed to cause low-grade 
inflammation and altered permeability in IBS. In fact, 
in some patients, IBS was related to food allergy[190]. 
Furthermore, endogenous triggers, such as MC-
derived histamine, proteases, and eicosanoids, could 
increase intestinal permeability, either directly or via 
the stimulation of neurons of the enteric nervous 
system[183]. Moreover, serotonin was also identified 
as an endogenous trigger of pain, inflammation, and 
increased permeability in IBS[40]; therefore, LX1031, an 
oral inhibitor of tryptophan hydroxylase, the principal 
enzyme needed for mucosal serotonin synthesis, has 
been successful for treatment of patients with non-
Sinagra E et al . Inflammation in IBS
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constipating IBS[191].
Enteric nerves 
Few studies have investigated the role of calcitonin 
gene related peptide and substance P. Wang et al[37] 
investigated the incidence of IBS in patients who 
had recovered from bacillary dysentery by focusing 
on neuroimmunologic changes, including changes in 
interleukins, MCs, neuropeptides, and the relationship 
between MCs and intestinal nerves[50]. The density of 
substance P-immunoreactive fibers was increased in 
both the ileal and the rectosigmoid samples of IBS 
patients[37], but the density of calcitonin gene related 
peptide-containing fibers remained unchanged. 
Palsson and coworkers[192] reported similar findings, 
and Kerkhoffs and coworkers[193] reported an increase 
of rectal substance P. However, these findings have not 
been universal[192,194], possibly reflecting region-specific 
discrepancies[51].
Neuronal plasticity in the enteric nervous system 
has also been investigated[195]. Akbar et al[38] 
investigated the capsaicin receptor transient receptor 
potential vanilloid 1-immunoreactive nerve fibers in 
colonic biopsies from patients with IBS. Specifically, 
they demonstrated that the number of nerve fibers 
exhibiting immunoreactivity for substance P and 
transient receptor potential vanilloid 1 was increased in 
IBS patients. Moreover, the number of these fibers did 
not differ by IBS subtype, but significantly correlated 
with patient pain scores[50,196].
Nerve growth factor has also been suggested 
to play a central role in promoting the growth and 
differentiation of primary afferent fibers[50]. Specifically, 
its expression was found to be markedly increased 
in rectal biopsies from pediatric[197] and adult IBS 
patients[198], suggesting both the sprouting of sensory 
afferent fibers expressing transient receptor potential 
vanilloid 1 and increases in receptor sensitivity in IBS, 
which consequently induced visceral hyperalgesia[50]. 
More recently, Dothel et al[199] also showed that 
nerve fiber density and sprouting, as well as the 
expression of nerve growth and neurotrophic tyrosine 
kinase receptor type 1, are significantly increased 
in the mucosal tissues of patients with IBS. Mucosal 
mediators participate in these neuroplastic changes.
Finally, the morphology of enteric glia, which are 
known to regulate intestinal barrier integrity and 
neuronal activity[200] has only been examined in one 
study of human intestinal biopsy samples from IBS 
patients and was found to be unchanged[50,201].
CONCLUSION
Low-grade intestinal inflammation plays a key role 
in the pathophysiology of IBS, and this role is likely 
multifactorial[202]. Several studies demonstrated 
microscopic and molecular abnormalities in IBS 
patients[202,203].
The above-reported evidence provides a rationale 
to test the efficacy of intestinal anti-inflammatory 
compounds in patients with IBS. Previously, treatment 
with corticosteroids was found to be ineffective in PI-
IBS patients[204]; however, MC stabilizers have produced 
promising results, particularly in IBS-D, suggesting 
that immune mechanisms and MCs are involved in 
the generation of IBS symptoms[205,206]. Based on this 
approach, Clarke and coworkers[207] recently conducted 
a phase 3, multicenter, tertiary setting, randomized, 
double-blind, placebo-controlled trial in patients with 
Rome Ⅲ-confirmed IBS to evaluate the efficacy and 
safety of mesalazine in patients with IBS. In this study, 
mesalazine treatment was not superior to placebo 
based on the study primary endpoint (68.6% vs 
67.4%, 95%CI: 12.8-15.1, P = 0.870). However, the 
placebo response was high in this trial and this study 
enrolled both male and female subjects and patients 
with mild symptoms[207], which likely masked drug 
efficacy. Furthermore, a subgroup of patients with IBS 
showed a sustained therapy response and benefits 
from mesalazine therapy[207].
As mentioned above, abnormalities in the enteric 
nervous system of the gut may alter digestion, 
gastrointestinal motility, and visceral hypersensitivity, 
which contribute to symptom onset and play a pivotal 
A B
Figure 5  Immunohistochemistry for chromogranin A showing increased expression in nerve terminals at the level of the basal membrane in the large 
intestine in inflammatory bowel disease. A: Irritable bowel syndrome patient; B: Control patient (× 40 magnification). Courtesy of Giancarlo Pompei, personal data.
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role in the pathogenesis of IBS[12].
The enteric nervous system of the gut seems to be 
affected by genetic differences, diet, intestinal flora, 
and inflammation[12]. For example, the food content 
of FODMAPs and fibers, which interacts with the 
intestinal flora and drives subsequent fermentation, 
may increase intestinal osmotic pressure to induce 
hormonal and serotonin release[12]. Targeting these 
known factors may improve the control of IBS 
symptoms by acting on mechanisms that trigger these 
symptoms and regulate the pathophysiology of IBS. 
Finally, probiotics have also been found to be effective 
in select IBS patients, as suggested by several recent 
systematic reviews, guidelines and meta-analyses, by 
improving intestinal permeability[208-212].
In conclusion, a high proportion of IBS patients 
show low-grade inflammation, which is a multifactorial 
process, in the intestinal mucosa. Understanding the 
mechanisms underlying the low-grade inflammation 
in IBS may allow the design of clinical trials that 
test the efficacy and safety of drugs that target the 
pathophysiologic mechanism of this disease.
REFERENCES
1 Sinagra E, Romano C, Cottone M. Psychopharmacological 
treatment and psychological interventions in irritable bowel 
syndrome. Gastroenterol Res Pract 2012; 2012: 486067 [PMID: 
22956940 DOI: 10.1155/2012/486067]
2 Stamboldjiev T. Management of Irritable Bowel Syndrome in 
Primary Care. Mas-ter of Arts in Nursing Theses 2011: 10 Available 
from: URL: http://sophia.stkate.edu/ma_nursing/10
3 Russo MW, Gaynes BN, Drossman DA. A national survey of 
practice patterns of gastroenterologists with comparison to the 
past two decades. J Clin Gastroenterol 1999; 29: 339-343 [PMID: 
10599638]
4 Wald A, Rakel D. Behavioral and complementary approaches for 
the treatment of irritable bowel syndrome. Nutr Clin Pract 1999; 23: 
284-292 [PMID: 18595861 DOI: 10.1177/0884533608318677]
5 Mulak A, Tachè Y. Sex difference in irritable bowel syndrome: do 
gonadal hormones play a role? Gastroenterol Pol 2010; 17: 89-97 
[PMID: 25435761]
6 Heitkemper M, Jarrett M, Bond EF, Chang L. Impact of sex and 
gender on irritable bowel syndrome. Biol Res Nurs 2003; 5: 56-65 
[PMID: 12886671]
7 Longstreth GF, Wolde-Tsadik G. Irritable bowel-type symptoms in 
HMO examinees. Prevalence, demographics, and clinical correlates. 
Dig Dis Sci 1993; 38: 1581-1589 [PMID: 8359067]
8 Toner BB, Akman D. Gender role and irritable bowel syndrome: 
literature review and hypothesis. Am J Gastroenterol 2000; 95: 11-16 
[PMID: 10638553]
9 Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin 
F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 
130: 1480-1491 [PMID: 16678561]
10 Lewis SJ, Heaton KW. Stool form scale as a useful guide to 
intestinal transit time. Scand J Gastroenterol 1997; 32: 920-924 
[PMID: 9299672]
11 El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Irritable 
bowel syndrome: diagnosis, pathogenesis and treatment options. 
New York: Nova Science Publishers, 2012
12 El-Salhy M, Gundersen D, Gilja OH, Hatlebakk JG, Hausken T. Is 
irritable bowel syndrome an organic disorder? World J Gastroenterol 
2014; 20: 384-400 [PMID: 24574708 DOI: 10.3748/wjg.v20.i2.384]
13 Lee YJ, Park KS. Irritable bowel syndrome: emerging paradigm in 
pathophysiology. World J Gastroenterol 2014; 20: 2456-2469 [PMID: 
24627583 DOI: 10.3748/wjg.v20.i10.2456]
14 Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA 
technical review on irritable bowel syndrome. Gastroenterology 
2002; 123: 2108-2131 [PMID: 12454866]
15 Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, 
Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P. Guidelines 
on the irritable bowel syndrome: mechanisms and practical 
management. Gut 2007; 56: 1770-1798 [PMID: 17488783]
16 Fukudo S, Kaneko H, Akiho H, Inamori M, Endo Y, Okumura 
T, Kanazawa M, Kamiya T, Sato K, Chiba T, Furuta K, Yamato 
S, Arakawa T, Fujiyama Y, Azuma T, Fujimoto K, Mine T, 
Miura S, Kinoshita Y, Sugano K, Shimosegawa T. Evidence-
based clinical practice guidelines for irritable bowel syndrome. J 
Gastroenterol 2015; 50: 11-30 [PMID: 25500976 DOI: 10.1007/
s00535-014-1017-0]
17 Ishihara S, Yashima K, Kushiyama Y, Izumi A, Kawashima K, 
Fujishiro H, Kojo H, Komazawa Y, Hamamoto T, Yamamoto T, 
Sasaki Y, Shimizu T, Okamoto E, Yoshimura T, Furuta K, Noguchi 
N, Tanaka H, Murawaki Y, Kinoshita Y. Prevalence of organic 
colonic lesions in patients meeting Rome III criteria for diagnosis 
of IBS: a prospective multi-center study utilizing colonoscopy. 
J Gastroenterol 2012; 47: 1084-1090 [PMID: 22460220 DOI: 
10.1007/s00535-012-0573-4]
18 Hsiao CW, Huang WY, Ke TW, Muo CH, Chen WT, Sung FC, Kao 
CH. Association between irritable bowel syndrome and colorectal 
cancer: a nationwide population-based study. Eur J Intern Med 2014; 
25: 82-86 [PMID: 24268837 DOI: 10.1016/j.ejim.2013.11.005]
19 Ahn E, Son KY, Shin DW, Han MK, Lee H, An AR, Kim EH, Cho B. 
Perceived risk as a barrier to appropriate diagnosis of irritable bowel 
syndrome. World J Gastroenterol 2014; 20: 18360-18366 [PMID: 
25561803 DOI: 10.3748/wjg.v20.i48.18360]
20 Lieberman DA, Williams JL, Holub JL, Morris CD, Logan JR, 
Eisen GM, Carney P. Colonoscopy utilization and outcomes 2000 
to 2011. Gastrointest Endosc 2014; 80: 133-143 [PMID: 24565067 
DOI: 10.1016/j.gie.2014.01.014]
21 McKenna BJ. Is it really colitis? Dealing with the nearly normal 
colonic biopsy and variations of microscopic colitis. Pathol Case 
Rev 2004; 9: 106-114 [DOI: 10.1097/01.pcr.0000126995.27683.bf]
22 Kirsch R, Riddell RH. Histopathological alterations in irritable 
bowel syndrome. Mod Pathol 2006; 19: 1638-1645 [PMID: 
17013373]
23 Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. 
A role for inflammation in irritable bowel syndrome? Gut 2002; 51 
Suppl 1: i41-i44 [PMID: 12077063]
24 Lee E, Schiller LR, Fordtran JS. Quantification of colonic lamina 
propria cells by means of a morphometric point-counting method. 
Gastroenterology 1988; 94: 409-418 [PMID: 3335315]
25 Salzmann JL, Peltier-Koch F, Bloch F, Petite JP, Camilleri JP. 
Morphometric study of colonic biopsies: a new method of estimating 
inflammatory diseases. Lab Invest 1989; 60: 847-851 [PMID: 
2733385]
26 O’Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, 
McLaren A, O’Morain CA. Increased mast cells in the irritable 
bowel syndrome. Neurogastroenterol Motil 2000; 12: 449-457 
[PMID: 11012945]
27 Piche T, Saint-Paul MC, Dainese R, Marine-Barjoan E, Iannelli 
A, Montoya ML, Peyron JF, Czerucka D, Cherikh F, Filippi J, 
Tran A, Hébuterne X. Mast cells and cellularity of the colonic 
mucosa correlated with fatigue and depression in irritable bowel 
syndrome. Gut 2008; 57: 468-473 [PMID: 18194987 DOI: 10.1136/
gut.2007.127068]
28 Ford AC, Talley NJ. Mucosal inflammation as a potential 
etiological factor in irritable bowel syndrome: a systematic review. J 
Gastroenterol 2011; 46: 421-431 [PMID: 21331765 DOI: 10.1007/
s00535-011-0379-9]
29 Walker MM, Talley NJ, Prabhakar M, Pennaneac’h CJ, Aro P, 
Ronkainen J, Storskrubb T, Harmsen WS, Zinsmeister AR, Agreus L. 
Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis 
as possible disease markers in the irritable bowel syndrome and 
functional dyspepsia. Aliment Pharmacol Ther 2009; 29: 765-773 
Sinagra E et al . Inflammation in IBS
2250 February 21, 2016|Volume 22|Issue 7|WJG|www.wjgnet.com
[PMID: 19183150 DOI: 10.1111/j.1365-2036.2009.03937.x]
30 Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review 
and meta-analysis of the prevalence of irritable bowel syndrome 
in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010; 8: 
401-409 [PMID: 19631762 DOI: 10.1016/j.cgh.2009.07.020]
31 Lembo AJ, Neri B, Tolley J, Barken D, Carroll S, Pan H. Use of 
serum biomarkers in a diagnostic test for irritable bowel syndrome. 
Aliment Pharmacol Ther 2009; 29: 834-842 [PMID: 19226291 DOI: 
10.1111/j.1365-2036.2009.03975.x]
32 Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, 
Ardid D. Review article: Associations between immune activation, 
intestinal permeability and the irritable bowel syndrome. Aliment 
Pharmacol Ther 2012; 36: 1009-1031 [PMID: 23066886 DOI: 
10.1111/apt.12080]
33 Hiatt RB, Katz L. Mast cells in inflammatory conditions of the 
gastrointestinal tract. Am J Gastroenterol 1962; 37: 541-545 [PMID: 
13907162]
34 De Giorgio R, Barbara G. Is irritable bowel syndrome an 
inflammatory disorder? Curr Gastroenterol Rep 2008; 10: 385-390 
[PMID: 18627650]
35 Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, 
psychological, and histological features of postinfective irritable 
bowel syndrome. Am J Gastroenterol 2003; 98: 1578-1583 [PMID: 
12873581]
36 Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, Rhee JC. 
Mucosal mast cell counts correlate with visceral hypersensitivity 
in patients with diarrhea predominant irritable bowel syndrome. J 
Gastroenterol Hepatol 2006; 21: 71-78 [PMID: 16706815]
37 Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative 
factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 
53: 1096-1101 [PMID: 15247174]
38 Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. 
Increased capsaicin receptor TRPV1-expressing sensory fibres 
in irritable bowel syndrome and their correlation with abdominal 
pain. Gut 2008; 57: 923-929 [PMID: 18252749 DOI: 10.1136/
gut.2007.138982]
39 Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di 
Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, Bunnett 
NW, Grundy D, Corinaldesi R. Mast cell-dependent excitation of 
visceral-nociceptive sensory neurons in irritable bowel syndrome. 
Gastroenterology 2007; 132: 26-37 [PMID: 17241857]
40 Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De Giorgio 
R, Stanghellini V, Grundy D, Tonini M, De Ponti F, Corinaldesi R, 
Barbara G. Intestinal serotonin release, sensory neuron activation, 
and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 
2011; 106: 1290-1298 [PMID: 21427712 DOI: 10.1038/ajg.2011.86]
41 Buhner S, Li Q, Vignali S, Barbara G, De Giorgio R, Stanghellini 
V, Cremon C, Zeller F, Langer R, Daniel H, Michel K, Schemann 
M. Activation of human enteric neurons by supernatants of colonic 
biopsy specimens from patients with irritable bowel syndrome. 
Gastroenterology 2009; 137: 1425-1434 [PMID: 19596012 DOI: 
10.1053/j.gastro.2009.07.005]
42 Coëffier M, Gloro R, Boukhettala N, Aziz M, Lecleire S, Vandaele 
N, Antonietti M, Savoye G, Bôle-Feysot C, Déchelotte P, Reimund 
JM, Ducrotté P. Increased proteasome-mediated degradation of 
occludin in irritable bowel syndrome. Am J Gastroenterol 2010; 105: 
1181-1188 [PMID: 19997094 DOI: 10.1038/ajg.2009.700]
43 Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro 
RF, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G. Mucosal 
immune activation in irritable bowel syndrome: gender-dependence 
and association with digestive symptoms. Am J Gastroenterol 2009; 
104: 392-400 [PMID: 19174797 DOI: 10.1038/ajg.2008.94]
44 Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, 
Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett 
NW, Collins SM, Corinaldesi R. Activated mast cells in proximity 
to colonic nerves correlate with abdominal pain in irritable bowel 
syndrome. Gastroenterology 2004; 126: 693-702 [PMID: 14988823]
45 Vivinus-Nébot M, Dainese R, Anty R, Saint-Paul MC, Nano JL, 
Gonthier N, Marjoux S, Frin-Mathy G, Bernard G, Hébuterne X, 
Tran A, Theodorou V, Piche T. Combination of allergic factors can 
worsen diarrheic irritable bowel syndrome: role of barrier defects 
and mast cells. Am J Gastroenterol 2012; 107: 75-81 [PMID: 
21931380 DOI: 10.1038/ajg.2011.315]
46 Wang SH, Dong L, Luo JY, Gong J, Li L, Lu XL, Han SP. 
Decreased expression of serotonin in the jejunum and increased 
numbers of mast cells in the terminal ileum in patients with irritable 
bowel syndrome. World J Gastroenterol 2007; 13: 6041-6047 [PMID: 
18023097 DOI: 10.3748/wjg.v13.45.6041]
47 Martínez C, Vicario M, Ramos L, Lobo B, Mosquera JL, Alonso 
C, Sánchez A, Guilarte M, Antolín M, de Torres I, González-Castro 
AM, Pigrau M, Saperas E, Azpiroz F, Santos J. The jejunum of 
diarrhea-predominant irritable bowel syndrome shows molecular 
alterations in the tight junction signaling pathway that are associated 
with mucosal pathobiology and clinical manifestations. Am J 
Gastroenterol 2012; 107: 736-746 [PMID: 22415197 DOI: 10.1038/
ajg.2011.472]
48 Martínez C, Lobo B, Pigrau M, Ramos L, González-Castro AM, 
Alonso C, Guilarte M, Guilá M, de Torres I, Azpiroz F, Santos J, 
Vicario M. Diarrhoea-predominant irritable bowel syndrome: an 
organic disorder with structural abnormalities in the jejunal epithelial 
barrier. Gut 2013; 62: 1160-1168 [PMID: 22637702 DOI: 10.1136/
gutjnl-2012-302093]
49 Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos 
L, Martínez C, Casellas F, Saperas E, Malagelada JR. Diarrhoea-
predominant IBS patients show mast cell activation and hyperplasia 
in the jejunum. Gut 2007; 56: 203-209 [PMID: 17005763]
50 Nasser Y, Boeckxstaens GE, Wouters MM, Schemann M, Vanner S. 
Using human intestinal biopsies to study the pathogenesis of irritable 
bowel syndrome. Neurogastroenterol Motil 2014; 26: 455-469 
[PMID: 24602069 DOI: 10.1111/nmo.12316]
51 Schemann M, Camilleri M. Functions and imaging of mast cell 
and neural axis of the gut. Gastroenterology 2013; 144: 698-704.e4 
[PMID: 23354018 DOI: 10.1053/j.gastro.2013.01.040]
52 Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner 
M, Neal KR. Increased rectal mucosal enteroendocrine cells, T 
lymphocytes, and increased gut permeability following acute 
Campylobacter enteritis and in post-dysenteric irritable bowel 
syndrome. Gut 2000; 47: 804-811 [PMID: 11076879]
53 Kim HS, Lim JH, Park H, Lee SI. Increased immunoendocrine 
cells in intestinal mucosa of postinfectious irritable bowel syndrome 
patients 3 years after acute Shigella infection--an observation in 
a small case control study. Yonsei Med J 2010; 51: 45-51 [PMID: 
20046513 DOI: 10.3349/ymj.2010.51.1.45]
54 Ohman L, Isaksson S, Lindmark AC, Posserud I, Stotzer PO, Strid 
H, Sjövall H, Simrén M. T-cell activation in patients with irritable 
bowel syndrome. Am J Gastroenterol 2009; 104: 1205-1212 [PMID: 
19367268 DOI: 10.1038/ajg.2009.116]
55 Törnblom H, Lindberg G, Nyberg B, Veress B. Full-thickness 
biopsy of the jejunum reveals inflammation and enteric neuropathy 
in irritable bowel syndrome. Gastroenterology 2002; 123: 1972-1979 
[PMID: 12454854]
56 Foley S, Garsed K, Singh G, Duroudier NP, Swan C, Hall IP, 
Zaitoun A, Bennett A, Marsden C, Holmes G, Walls A, Spiller RC. 
Impaired uptake of serotonin by platelets from patients with irritable 
bowel syndrome correlates with duodenal immune activation. 
Gastroenterology 2011; 140: 1434-1443.e1 [PMID: 21315720 DOI: 
10.1053/j.gastro.2011.01.052]
57 Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, 
Wilson I. Activation of the mucosal immune system in irritable 
bowel syndrome. Gastroenterology 2002; 122: 1778-1783 [PMID: 
12055584]
58 Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW. 
The alteration of enterochromaffin cell, mast cell, and lamina 
propria T lymphocyte numbers in irritable bowel syndrome 
and its relationship with psychological factors. J Gastroenterol 
Hepatol 2008; 23: 1689-1694 [PMID: 19120860 DOI: 10.1111/
j.1440-1746.2008.05574.x]
59 Faure C, Patey N, Gauthier C, Brooks EM, Mawe GM. Serotonin 
signaling is altered in irritable bowel syndrome with diarrhea but not 
in functional dyspepsia in pediatric age patients. Gastroenterology 
Sinagra E et al . Inflammation in IBS
2251 February 21, 2016|Volume 22|Issue 7|WJG|www.wjgnet.com
2010;  139 :  249-258 [PMID: 20303355 DOI:  10.1053/
j.gastro.2010.03.032]
60 Park JH, Rhee PL, Kim G, Lee JH, Kim YH, Kim JJ, Rhee JC, 
Song SY. Enteroendocrine cell counts correlate with visceral 
hypersensitivity in patients with diarrhoea-predominant irritable 
bowel syndrome. Neurogastroenterol Motil 2006; 18: 539-546 
[PMID: 16771769]
61 Park H. [The pathophysiology of irritable bowel syndrome: 
inflammation and motor disorder]. Korean J Gastroenterol 2006; 47: 
101-110 [PMID: 16498275]
62 Forshammar J, Isaksson S, Strid H, Stotzer PO, Sjövall H, Simrén 
M, Ohman L. A pilot study of colonic B cell pattern in irritable 
bowel syndrome. Scand J Gastroenterol 2008; 43: 1461-1466 
[PMID: 18663666 DOI: 10.1080/00365520802272126]
63 Steinman RM. The dendritic cell system and its role in immuno-
genicity. Annu Rev Immunol 1991; 9: 271-296 [PMID: 1910679]
64 Adams S, O’Neill DW, Bhardwaj N. Recent advances in dendritic 
cell biology. J Clin Immunol 2005; 25: 177-188 [PMID: 16118915]
65 Koido S, Ohkusa T, Kan S, Takakura K, Saito K, Komita H, Ito Z, 
Kobayashi H, Takami S, Uchiyama K, Arakawa H, Ito M, Okamoto 
M, Kajihara M, Homma S, Tajiri H. Production of corticotropin-
releasing factor and urocortin from human monocyte-derived 
dendritic cells is stimulated by commensal bacteria in intestine. 
World J Gastroenterol 2014; 20: 14420-14429 [PMID: 25339828 
DOI: 10.3748/wjg.v20.i39.14420]
66 Long Y, Wang W, Wang H, Hao L, Qian W, Hou X. Characteristics 
of intestinal lamina propria dendritic cells in a mouse model 
of postinfectious irritable bowel syndrome. J Gastroenterol 
Hepatol 2012; 27: 935-944 [PMID: 22141367 DOI: 10.1111/
j.1440-1746.2011.07046.x]
67 Beatty JK, Bhargava A, Buret AG. Post-infectious irritable bowel 
syndrome: mechanistic insights into chronic disturbances following 
enteric infection. World J Gastroenterol 2014; 20: 3976-3985 [PMID: 
24744587 DOI: 10.3748/wjg.v20.i14.3976]
68 Ji S, Park H, Lee D, Song YK, Choi JP, Lee SI. Post-infectious 
irritable bowel syndrome in patients with Shigella infection. J 
Gastroenterol Hepatol 2005; 20: 381-386 [PMID: 15740480]
69 Kim HS, Kim MS, Ji SW, Park H. [The development of irritable 
bowel syndrome after Shigella infection: 3 year follow-up study]. 
Korean J Gastroenterol 2006; 47: 300-305 [PMID: 16632982]
70 Kindt S, Van Oudenhove L, Broekaert D, Kasran A, Ceuppens 
JL, Bossuyt X, Fischler B, Tack J. Immune dysfunction in patients 
with functional gastrointestinal disorders. Neurogastroenterol 
Motil 2009; 21: 389-398 [PMID: 19126184 DOI: 10.1111/
j.1365-2982.2008.01220.x]
71 Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester 
S, Downie-Doyle S, Smith E, Drew P, Talley NJ, Holtmann G. 
Immune activation in patients with irritable bowel syndrome. 
Gastroenterology 2007; 132: 913-920 [PMID: 17383420]
72 Miao EA, Rajan JV. Salmonella and Caspase-1: A complex Interplay 
of Detection and Evasion. Front Microbiol 2011; 2: 85 [PMID: 
21833326 DOI: 10.3389/fmicb.2011.00085]
73 Moran GW, Leslie FC, Levison SE, Worthington J, McLaughlin 
JT. Enteroendocrine cells: neglected players in gastrointestinal 
disorders? Therap Adv Gastroenterol 2008; 1: 51-60 [PMID: 
21180514 DOI: 10.1177/1756283X08093943]
74 Rindi G, Inzani F, Solcia E. Pathology of gastrointestinal disorders. 
Endocrinol Metab Clin North Am 2010; 39: 713-727 [PMID: 
21095540 DOI: 10.1016/j.ecl.2010.08.009]
75 Gunnarsson J, Simrén M. Peripheral factors in the pathophysiology 
of irritable bowel syndrome. Dig Liver Dis 2009; 41: 788-793 [PMID: 
19665956 DOI: 10.1016/j.dld.2009.07.006]
76 Delgado-Aros S, Camilleri M. Visceral hypersensitivity. J Clin 
Gastroenterol 2005; 39: S194-S203; discussion S210 [PMID: 
15798485]
77 Lee OY. Asian motility studies in irritable bowel syndrome. J 
Neurogastroenterol Motil 2010; 16: 120-130 [PMID: 20535342 
DOI: 10.5056/jnm.2010.16.2.120]
78 Posserud I, Syrous A, Lindström L, Tack J, Abrahamsson H, 
Simrén M. Altered rectal perception in irritable bowel syndrome 
is associated with symptom severity. Gastroenterology 2007; 133: 
1113-1123 [PMID: 17919487]
79 Ritchie J. Pain from distension of the pelvic colon by inflating a 
balloon in the irritable colon syndrome. Gut 1973; 14: 125-132 
[PMID: 4696535]
80 Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered 
rectal perception is a biological marker of patients with irritable 
bowel syndrome. Gastroenterology 1995; 109: 40-52 [PMID: 
7797041]
81 Whitehead WE, Palsson OS. Is rectal pain sensitivity a biological 
marker for irritable bowel syndrome: psychological influences on 
pain perception. Gastroenterology 1998; 115: 1263-1271 [PMID: 
9797383]
82 Whitehead WE, Holtkotter B, Enck P, Hoelzl R, Holmes KD, 
Anthony J, Shabsin HS, Schuster MM. Tolerance for rectosigmoid 
distention in irritable bowel syndrome. Gastroenterology 1990; 98: 
1187-1192 [PMID: 2323511]
83 Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganière M, 
Verrier P, Poitras P. Rectal distention testing in patients with irritable 
bowel syndrome: sensitivity, specificity, and predictive values of 
pain sensory thresholds. Gastroenterology 2002; 122: 1771-1777 
[PMID: 12055583]
84 Bradette M, Delvaux M, Staumont G, Fioramonti J, Bueno L, 
Frexinos J. Evaluation of colonic sensory thresholds in IBS patients 
using a barostat. Definition of optimal conditions and comparison 
with healthy subjects. Dig Dis Sci 1994; 39: 449-457 [PMID: 
8131679]
85 Camilleri M, McKinzie S, Busciglio I, Low PA, Sweetser S, Burton 
D, Baxter K, Ryks M, Zinsmeister AR. Prospective study of motor, 
sensory, psychologic, and autonomic functions in patients with 
irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 
772-781 [PMID: 18456567 DOI: 10.1016/j.cgh.2008.02.060]
86 Wendelbo I, Mazzawi T, El-Salhy M. Increased serotonin 
transporter immunoreactivity intensity in the ileum of patients with 
irritable bowel disease. Mol Med Rep 2014; 9: 180-184 [PMID: 
24213511]
87 Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, 
Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, 
Moses PL. Molecular defects in mucosal serotonin content and 
decreased serotonin reuptake transporter in ulcerative colitis and 
irritable bowel syndrome. Gastroenterology 2004; 126: 1657-1664 
[PMID: 15188158]
88 El-Salhy M, Wendelbo IH, Gundersen D. Reduced chromogranin A 
cell density in the ileum of patients with irritable bowel syndrome. 
Mol Med Rep 2013; 7: 1241-1244 [PMID: 23426642 DOI: 10.3892/
mmr.2013.1325]
89 Chen JX, Pan H, Rothman TP, Wade PR, Gershon MD. Guinea pig 
5-HT transporter: cloning, expression, distribution, and function in 
intestinal sensory reception. Am J Physiol 1998; 275: G433-G448 
[PMID: 9724254]
90 Keating C, Beyak M, Foley S, Singh G, Marsden C, Spiller R, 
Grundy D. Afferent hypersensitivity in a mouse model of post-
inflammatory gut dysfunction: role of altered serotonin metabolism. 
J Physiol 2008; 586: 4517-4530 [PMID: 18653657 DOI: 10.1113/
jphysiol.2008.156984]
91 Coleman NS, Foley S, Dunlop SP, Wheatcroft J, Blackshaw E, 
Perkins AC, Singh G, Marsden CA, Holmes GK, Spiller RC. 
Abnormalities of serotonin metabolism and their relation to 
symptoms in untreated celiac disease. Clin Gastroenterol Hepatol 
2006; 4: 874-881 [PMID: 16797248]
92 Gershon MD, Tack J. The serotonin signaling system: from basic 
understanding to drug development for functional GI disorders. 
Gastroenterology 2007; 132: 397-414 [PMID: 17241888 DOI: 
10.1053/j.gastro.2006.11.002]
93 Whorwell PJ, Clouter C, Smith CL. Oesophageal motility in the 
irritable bowel syndrome. Br Med J (Clin Res Ed) 1981; 282: 
1101-1102 [PMID: 6786454]
94 Clouse RE, Eckert TC. Gastrointestinal symptoms of patients with 
esophageal contraction abnormalities. Dig Dis Sci 1986; 31: 236-240 
[PMID: 3948627]
Sinagra E et al . Inflammation in IBS
2252 February 21, 2016|Volume 22|Issue 7|WJG|www.wjgnet.com
95 Soffer EE, Scalabrini P, Pope CE, Wingate DL. Effect of stress on 
oesophageal motor function in normal subjects and in patients with 
the irritable bowel syndrome. Gut 1988; 29: 1591-1594 [PMID: 
3209118]
96 Lind CD. Motility disorders in the irritable bowel syndrome. 
Gastroenterol Clin North Am 1991; 20: 279-295 [PMID: 2066153]
97 van Wijk HJ, Smout AJ, Akkermans LM, Roelofs JM, ten Thije 
OJ. Gastric emptying and dyspeptic symptoms in the irritable 
bowel syndrome. Scand J Gastroenterol 1992; 27: 99-102 [PMID: 
1561533]
98 Charles F, Phillips SF, Camilleri M, Thomforde GM. Rapid 
gastric emptying in patients with functional diarrhea. Mayo 
Clin Proc 1997; 72: 323-328 [PMID: 9121178 DOI: 10.1016/
s0025-6196(11)63331-4]
99 Caballero-Plasencia AM, Valenzuela-Barranco M, Herrerías-
Gutiérrez JM, Esteban-Carretero JM. Altered gastric emptying in 
patients with irritable bowel syndrome. Eur J Nucl Med 1999; 26: 
404-409 [PMID: 10199947]
100 Morin DR. The patient’s records and the defense of dental 
malpractice claims. Am J Orthod Dentofacial Orthop 1992; 102: 
569-570 [PMID: 1456239]
101 Stanghellini V, Tosetti C, Barbara G, De Giorgio R, Cogliandro 
L, Cogliandro R, Corinaldesi R. Dyspeptic symptoms and gastric 
emptying in the irritable bowel syndrome. Am J Gastroenterol 
2002; 97 :  2738-2743 [PMID: 12425541 DOI: 10.1111/
j.1572-0241.2002.07062.x]
102 Leahy A, Besherdas K, Clayman C, Mason I, Epstein O. 
Abnormalities of the electrogastrogram in functional gastrointestinal 
disorders. Am J Gastroenterol 1999; 94: 1023-1028 [PMID: 
10201477 DOI: 10.1111/j.1572-0241.1999.01007.x]
103 Evans PR, Bak YT, Shuter B, Hoschl R, Kellow JE. Gastroparesis 
and small bowel dysmotility in irritable bowel syndrome. Dig Dis 
Sci 1997; 42: 2087-2093 [PMID: 9365140]
104 Nielsen OH, Gjørup T, Christensen FN. Gastric emptying rate and 
small bowel transit time in patients with irritable bowel syndrome 
determined with 99mTc-labeled pellets and scintigraphy. Dig Dis Sci 
1986; 31: 1287-1291 [PMID: 3803129]
105 Acharya U, Waite N, Howlett P, Tanner AR, Smith CL. Failure to 
demonstrate altered gastric emptying in irritable bowel syndrome. 
Dig Dis Sci 1983; 28: 889-892 [PMID: 6352205]
106 El-Salhy M. Ghrelin in gastrointestinal diseases and disorders: 
a possible role in the pathophysiology and clinical implications 
(review). Int J Mol Med 2009; 24: 727-732 [PMID: 19885611]
107 Asakawa A, Ataka K, Fujino K, Chen CY, Kato I, Fujimiya M, 
Inui A. Ghrelin family of peptides and gut motility. J Gastroenterol 
Hepatol 2011; 26 Suppl 3: 73-74 [PMID: 21443714 DOI: 10.1111/
j.1440-1746.2011.06638.x]
108 Dornonville de la Cour C, Lindström E, Norlén P, Håkanson R. 
Ghrelin stimulates gastric emptying but is without effect on acid 
secretion and gastric endocrine cells. Regul Pept 2004; 120: 23-32 
[PMID: 15177917 DOI: 10.1016/j.regpep.2004.02.008]
109 Fukuda H, Mizuta Y, Isomoto H, Takeshima F, Ohnita K, Ohba 
K, Omagari K, Taniyama K, Kohno S. Ghrelin enhances gastric 
motility through direct stimulation of intrinsic neural pathways and 
capsaicin-sensitive afferent neurones in rats. Scand J Gastroenterol 
2004; 39: 1209-1214 [PMID: 15742997]
110 Levin F, Edholm T, Schmidt PT, Grybäck P, Jacobsson H, Degerblad 
M, Höybye C, Holst JJ, Rehfeld JF, Hellström PM, Näslund E. 
Ghrelin stimulates gastric emptying and hunger in normal-weight 
humans. J Clin Endocrinol Metab 2006; 91: 3296-3302 [PMID: 
16772353 DOI: 10.1210/jc.2005-2638]
111 Edholm T, Levin F, Hellström PM, Schmidt PT. Ghrelin stimulates 
motility in the small intestine of rats through intrinsic cholinergic 
neurons. Regul Pept 2004; 121: 25-30 [PMID: 15256270 DOI: 
10.1016/j.regpep.2004.04.001]
112 Tack J, Depoortere I, Bisschops R, Delporte C, Coulie B, 
Meulemans A, Janssens J, Peeters T. Influence of ghrelin on 
interdigestive gastrointestinal motility in humans. Gut 2006; 55: 
327-333 [PMID: 16216827 DOI: 10.1136/gut.2004.060426]
113 Ariga H, Tsukamoto K, Chen C, Mantyh C, Pappas TN, Takahashi 
T. Endogenous acyl ghrelin is involved in mediating spontaneous 
phase III-like contractions of the rat stomach. Neurogastroenterol 
Motil 2007; 19: 675-680 [PMID: 17640183 DOI: 10.1111/
j.1365-2982.2007.00945.x]
114 Ariga H, Nakade Y, Tsukamoto K, Imai K, Chen C, Mantyh C, 
Pappas TN, Takahashi T. Ghrelin accelerates gastric emptying via 
early manifestation of antro-pyloric coordination in conscious rats. 
Regul Pept 2008; 146: 112-116 [PMID: 17913258 DOI: 10.1016/
j.regpep.2007.08.022]
115 Tümer C, Oflazoğlu HD, Obay BD, Kelle M, Taşdemir E. Effect 
of ghrelin on gastric myoelectric activity and gastric emptying in 
rats. Regul Pept 2008; 146: 26-32 [PMID: 17825442 DOI: 10.1016/
j.regpep.2007.07.008]
116 Tack JF, Janssens J, Vantrappen G, Wood JD. Actions of 
5-hydroxytryptamine on myenteric neurons in guinea pig gastric 
antrum. Am J Physiol 1992; 263: G838-G846 [PMID: 1476191]
117 Michel K, Sann H, Schaaf C, Schemann M. Subpopulations of 
gastric myenteric neurons are differentially activated via distinct 
serotonin receptors: projection, neurochemical coding, and functional 
implications. J Neurosci 1997; 17: 8009-8017 [PMID: 9315919]
118 Camilleri M. Integrated upper gastrointestinal response to food 
intake. Gastroenterology 2006; 131: 640-658 [PMID: 16890616 
DOI: 10.1053/j.gastro.2006.03.023]
119 Lal S, McLaughlin J, Barlow J, D’Amato M, Giacovelli G, Varro A, 
Dockray GJ, Thompson DG. Cholecystokinin pathways modulate 
sensations induced by gastric distension in humans. Am J Physiol 
Gastrointest Liver Physiol 2004; 287: G72-G79 [PMID: 14764444 
DOI: 10.1152/ajpgi.00351.2003]
120 Chey WY, Chang TM. Secretin, 100 years later. J Gastroenterol 
2003; 38: 1025-1035 [PMID: 14673718]
121 Cann PA, Read NW, Brown C, Hobson N, Holdsworth CD. Irritable 
bowel syndrome: relationship of disorders in the transit of a single 
solid meal to symptom patterns. Gut 1983; 24: 405-411 [PMID: 
6840614]
122 Sadik R, Stotzer PO, Simrén M, Abrahamsson H. Gastrointestinal 
transit abnormalities are frequently detected in patients with 
unexplained GI symptoms at a tertiary centre. Neurogastroenterol 
Motil 2008; 20: 197-205 [PMID: 17999649 DOI: 10.1111/
j.1365-2982.2007.01025.x]
123 Jian R, Najean Y, Bernier JJ. Measurement of intestinal progression 
of a meal and its residues in normal subjects and patients with 
functional diarrhoea by a dual isotope technique. Gut 1984; 25: 
728-731 [PMID: 6735253]
124 Corbett CL, Thomas S, Read NW, Hobson N, Bergman I, 
Holdsworth CD. Electrochemical detector for breath hydrogen 
determination: measurement of small bowel transit time in normal 
subjects and patients with the irritable bowel syndrome. Gut 1981; 
22: 836-840 [PMID: 7297914]
125 Kellow JE, Phillips SF, Miller LJ, Zinsmeister AR. Dysmotility 
of the small intestine in irritable bowel syndrome. Gut 1988; 29: 
1236-1243 [PMID: 3197998]
126 Kellow JE, Phillips SF. Altered small bowel motility in irritable 
bowel syndrome is correlated with symptoms. Gastroenterology 
1987; 92: 1885-1893 [PMID: 3569764]
127 Kellow JE, Gill RC, Wingate DL. Prolonged ambulant recordings of 
small bowel motility demonstrate abnormalities in the irritable bowel 
syndrome. Gastroenterology 1990; 98: 1208-1218 [PMID: 2323514]
128 Quigley EM, Donovan JP, Lane MJ, Gallagher TF. Antroduodenal 
manometry. Usefulness and limitations as an outpatient study. Dig 
Dis Sci 1992; 37: 20-28 [PMID: 1728526]
129 Quigley EM. Intestinal manometry--technical advances, clinical 
limitations. Dig Dis Sci 1992; 37: 10-13 [PMID: 1728512]
130 Gorard DA, Libby GW, Farthing MJ. Ambulatory small intestinal 
motility in ‘diarrhoea’ predominant irritable bowel syndrome. Gut 
1994; 35: 203-210 [PMID: 8307470]
131 Zhao JH, Dong L, Hao XQ. [Small intestine motility and 
gastrointestinal hormone levels in irritable bowel syndrome]. 
Nanfang Yike Daxue Xuebao 2007; 27: 1492-1495 [PMID: 
17959521]
132 Kellow JE, Eckersley CM, Jones MP. Enhanced perception of 
Sinagra E et al . Inflammation in IBS
2253 February 21, 2016|Volume 22|Issue 7|WJG|www.wjgnet.com
physiological intestinal motility in the irritable bowel syndrome. 
Gastroenterology 1991; 101: 1621-1627 [PMID: 1955127]
133 Thompson DG, Laidlow JM, Wingate DL. Abnormal small-bowel 
motility demonstrated by radiotelemetry in a patient with irritable 
colon. Lancet 1979; 2: 1321-1323 [PMID: 92671]
134 Kingham JG, Bown R, Colson R, Clark ML. Jejunal motility in 
patients with functional abdominal pain. Gut 1984; 25: 375-380 
[PMID: 6706216]
135 Schmidt T, Pfeiffer A, Kaess H. Abnormal intestinal motility in 
irritable bowel syndrome. Gastroenterology 1996; 111: 1400-1401 
[PMID: 8898662]
136 Schmidt T, Hackelsberger N, Widmer R, Meisel C, Pfeiffer 
A, Kaess H. Ambulatory 24-hour jejunal motility in diarrhea-
predominant irritable bowel syndrome. Scand J Gastroenterol 1996; 
31: 581-589 [PMID: 8789897]
137 Hellström PM, Näslund E, Edholm T, Schmidt PT, Kristensen 
J, Theodorsson E, Holst JJ, Efendic S. GLP-1 suppresses 
gastrointestinal motility and inhibits the migrating motor complex 
in healthy subjects and patients with irritable bowel syndrome. 
Neurogastroenterol Motil 2008; 20: 649-659 [PMID: 18298441 
DOI: 10.1111/j.1365-2982.2007.01079.x]
138 Simrén M, Castedal M, Svedlund J, Abrahamsson H, Björnsson E. 
Abnormal propagation pattern of duodenal pressure waves in the 
irritable bowel syndrome (IBS) [correction of (IBD)]. Dig Dis Sci 
2000; 45: 2151-2161 [PMID: 11215731]
139 Stanghellini V, Ghidini C, Maccarini MR, Paparo GF, Corinaldesi R, 
Barbara L. Fasting and postprandial gastrointestinal motility in ulcer 
and non-ulcer dyspepsia. Gut 1992; 33: 184-190 [PMID: 1541413]
140 Björnsson ES, Abrahamsson H. Interdigestive gastroduodenal 
manometry in humans. Indication of duodenal phase III as a 
retroperistaltic pump. Acta Physiol Scand 1995; 153: 221-230 
[PMID: 7625174 DOI: 10.1111/j.1748-1716.1995]
141 Maljaars PW, Keszthelyi D, Masclee AA. An ileal brake-through? 
Am J Clin Nutr 2010; 92: 467-468 [PMID: 20685954 DOI: 10.3945/
ajcn.2010.30180]
142 Van Citters GW, Lin HC. Ileal brake: neuropeptidergic control of 
intestinal transit. Curr Gastroenterol Rep 2006; 8: 367-373 [PMID: 
16968603]
143 Lin HC, Zhao XT, Wang L, Wong H. Fat-induced ileal brake in the 
dog depends on peptide YY. Gastroenterology 1996; 110: 1491-1495 
[PMID: 8613054]
144 Pironi L, Stanghellini V, Miglioli M, Corinaldesi R, De Giorgio R, 
Ruggeri E, Tosetti C, Poggioli G, Morselli Labate AM, Monetti N. 
Fat-induced ileal brake in humans: a dose-dependent phenomenon 
correlated to the plasma levels of peptide YY. Gastroenterology 
1993; 105: 733-739 [PMID: 8359644]
145 Spiller RC, Trotman IF, Adrian TE, Bloom SR, Misiewicz JJ, Silk 
DB. Further characterisation of the ‘ileal brake’ reflex in man--effect 
of ileal infusion of partial digests of fat, protein, and starch on jejunal 
motility and release of neurotensin, enteroglucagon, and peptide YY. 
Gut 1988; 29: 1042-1051 [PMID: 3410330]
146 Spiller RC, Trotman IF, Higgins BE, Ghatei MA, Grimble GK, Lee 
YC, Bloom SR, Misiewicz JJ, Silk DB. The ileal brake--inhibition 
of jejunal motility after ileal fat perfusion in man. Gut 1984; 25: 
365-374 [PMID: 6706215]
147 Goumain M, Voisin T, Lorinet AM, Ducroc R, Tsocas A, Rozé C, 
Rouet-Benzineb P, Herzog H, Balasubramaniam A, Laburthe M. 
The peptide YY-preferring receptor mediating inhibition of small 
intestinal secretion is a peripheral Y(2) receptor: pharmacological 
evidence and molecular cloning. Mol Pharmacol 2001; 60: 124-134 
[PMID: 11408607]
148 Souli A, Chariot J, Voisin T, Presset O, Tsocas A, Balasubramaniam 
A, Laburthe M, Rozé C. Several receptors mediate the antisecretory 
effect of peptide YY, neuropeptide Y, and pancreatic polypeptide 
on VIP-induced fluid secretion in the rat jejunum in vivo. Peptides 
1997; 18: 551-557 [PMID: 9210175]
149 Whang EE, Hines OJ, Reeve JR, Grandt D, Moser JA, Bilchik AJ, 
Zinner MJ, McFadden DW, Ashley SW. Antisecretory mechanisms 
of peptide YY in rat distal colon. Dig Dis Sci 1997; 42: 1121-1127 
[PMID: 9201071]
150 Konturek SJ, Konturek PC, Brzozowska I, Pawlik M, Sliwowski Z, 
Cześnikiewicz-Guzik M, Kwiecień S, Brzozowski T, Bubenik GA, 
Pawlik WW. Localization and biological activities of melatonin in 
intact and diseased gastrointestinal tract (GIT). J Physiol Pharmacol 
2007; 58: 381-405 [PMID: 17928638]
151 Thor PJ, Krolczyk G, Gil K, Zurowski D, Nowak L. Melatonin and 
serotonin effects on gastrointestinal motility. J Physiol Pharmacol 
2007; 58 Suppl 6: 97-103 [PMID: 18212403]
152 Lu WZ, Song GH, Gwee KA, Ho KY. The effects of melatonin on 
colonic transit time in normal controls and IBS patients. Dig Dis Sci 
2009; 54: 1087-1093 [PMID: 18720001 DOI: 10.1007/s10620-008-
0463-z]
153 Charles F, Camilleri M, Phillips SF, Thomforde GM, Forstrom LA. 
Scintigraphy of the whole gut: clinical evaluation of transit disorders. 
Mayo Clin Proc 1995; 70: 113-118 [PMID: 7845035 DOI: 10.1016/
s0025-6196(11)64277-8]
154 van der Sijp JR, Kamm MA, Nightingale JM, Britton KE, Mather 
SJ, Morris GP, Akkermans LM, Lennard-Jones JE. Radioisotope 
determination of regional colonic transit in severe constipation: 
comparison with radio opaque markers. Gut 1993; 34: 402-408 
[PMID: 8472991]
155 Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, 
Thomforde GM. Transit through the proximal colon influences stool 
weight in the irritable bowel syndrome. Gastroenterology 1992; 102: 
102-108 [PMID: 1727743]
156 Snape WJ, Carlson GM, Cohen S. Colonic myoelectric activity in 
the irritable bowel syndrome. Gastroenterology 1976; 70: 326-330 
[PMID: 765183]
157 Snape WJ. Myoelectric and motor activity of the colon in normal 
and abnormal states. Scand J Gastroenterol Suppl 1984; 96: 55-60 
[PMID: 6591381]
158 Sarna S, Latimer P, Campbell D, Waterfall WE. Effect of stress, 
meal and neostigmine on rectosigmoid electrical control activity 
(ECA) in normals and in irritable bowel syndrome patients. Dig Dis 
Sci 1982; 27: 582-591 [PMID: 7083996]
159 Latimer P, Sarna S, Campbell D, Latimer M, Waterfall W, Daniel 
EE. Colonic motor and myoelectrical activity: a comparative study 
of normal subjects, psychoneurotic patients, and patients with 
irritable bowel syndrome. Gastroenterology 1981; 80: 893-901 
[PMID: 7202974]
160 Welgan P, Meshkinpour H, Ma L. Role of anger in antral motor 
activity in irritable bowel syndrome. Dig Dis Sci 2000; 45: 248-251 
[PMID: 10711433]
161 Welgan P, Meshkinpour H, Hoehler F. The effect of stress on colon 
motor and electrical activity in irritable bowel syndrome. Psychosom 
Med 1985; 47: 139-149 [PMID: 4048360]
162 Katschinski M, Lederer P, Ellermann A, Ganzleben R, Lux 
G, Arnold R. Myoelectric and manometric patterns of human 
rectosigmoid colon in irritable bowel syndrome and diverticulosis. 
Scand J Gastroenterol 1990; 25: 761-768 [PMID: 2204105]
163 Chey WY, Jin HO, Lee MH, Sun SW, Lee KY. Colonic motility 
abnormality in patients with irritable bowel syndrome exhibiting 
abdominal pain and diarrhea. Am J Gastroenterol 2001; 96: 
1499-1506 [PMID: 11374689]
164 Vassallo MJ, Camilleri M, Phillips SF, Steadman CJ, Talley NJ, 
Hanson RB, Haddad AC. Colonic tone and motility in patients with 
irritable bowel syndrome. Mayo Clin Proc 1992; 67: 725-731 [PMID: 
1434910]
165 Corsetti M, Ogliari C, Marino B, Basilisco G. Perceptual sensitivity 
and response bias during rectal distension in patients with irritable 
bowel syndrome. Neurogastroenterol Motil 2005; 17: 541-547 
[PMID: 16078943 DOI: 10.1111/j.1365-2982.2005.00701.x]
166 Corsetti M, Cesana B, Bhoori S, Basilisco G. Rectal hyperreactivity 
to distention in patients with irritable bowel syndrome: role of 
distention rate. Clin Gastroenterol Hepatol 2004; 2: 49-56 [PMID: 
15017632]
167 Bassotti G, de Roberto G, Chistolini F, Sietchiping-Nzepa F, Morelli 
O, Morelli A. Twenty-four-hour manometric study of colonic 
propulsive activity in patients with diarrhea due to inflammatory 
(ulcerative colitis) and non-inflammatory (irritable bowel syndrome) 
Sinagra E et al . Inflammation in IBS
2254 February 21, 2016|Volume 22|Issue 7|WJG|www.wjgnet.com
conditions. Int J Colorectal Dis 2004; 19: 493-497 [PMID: 
15083326 DOI: 10.1007/s00384-004-0604-6]
168 Bassotti G, Sietchiping-Nzepa F, De Roberto G, Chistolini F, 
Morelli A. Colonic regular contractile frequency patterns in irritable 
bowel syndrome: the ‘spastic colon’ revisited. Eur J Gastroenterol 
Hepatol 2004; 16: 613-617 [PMID: 15167165]
169 Clemens CH, Samsom M, Van Berge Henegouwen GP, Smout AJ. 
Abnormalities of left colonic motility in ambulant nonconstipated 
patients with irritable bowel syndrome. Dig Dis Sci 2003; 48: 74-82 
[PMID: 12645793]
170 Clemens CH, Samsom M, Roelofs JM, van Berge Henegouwen GP, 
Smout AJ. Association between pain episodes and high amplitude 
propagated pressure waves in patients with irritable bowel syndrome. 
Am J Gastroenterol 2003; 98: 1838-1843 [PMID: 12907341 DOI: 
10.1111/j.1572-0241.2003.07541.x]
171 Rogers J, Henry MM, Misiewicz JJ. Increased segmental activity 
and intraluminal pressures in the sigmoid colon of patients with the 
irritable bowel syndrome. Gut 1989; 30: 634-641 [PMID: 2731756]
172 Simrén M, Abrahamsson H, Björnsson ES. An exaggerated sensory 
component of the gastrocolonic response in patients with irritable 
bowel syndrome. Gut 2001; 48: 20-27 [PMID: 11115818]
173 Di Stefano M, Miceli E, Missanelli A, Mazzocchi S, Corazza GR. 
Meal induced rectosigmoid tone modification: a low caloric meal 
accurately separates functional and organic gastrointestinal disease 
patients. Gut 2006; 55: 1409-1414 [PMID: 16434428 DOI: 10.1136/
gut.2005.076323]
174 Park JH, Baek YH, Park DI, Kim HJ, Cho YK, Sohn CI, Jeon WK, 
Kim BI, Rhee PL. Analysis of rectal dynamic and static compliances 
in patients with irritable bowel syndrome. Int J Colorectal Dis 2008; 
23: 659-664 [PMID: 18357460 DOI: 10.1007/s00384-008-0469-1]
175 Steens J, Van Der Schaar PJ, Penning C, Brussee J, Masclee AA. 
Compliance, tone and sensitivity of the rectum in different subtypes 
of irritable bowel syndrome. Neurogastroenterol Motil 2002; 14: 
241-247 [PMID: 12061908]
176 Kwan CL, Davis KD, Mikula K, Diamant NE. Abnormal rectal 
motor physiology in patients with irritable bowel syndrome. 
Neurogastroenterol Motil 2004; 16: 251-263 [PMID: 15086879 
DOI: 10.1111/j.1365-2982.2004.00508.x]
177 Cummings JH, Antoine JM, Azpiroz F, Bourdet-Sicard R, 
Brandtzaeg P, Calder PC, Gibson GR, Guarner F, Isolauri E, 
Pannemans D, Shortt C, Tuijtelaars S, Watzl B. PASSCLAIM--
gut health and immunity. Eur J Nutr 2004; 43 Suppl 2: II118-II173 
[PMID: 15221356]
178 Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, 
Serino M, Tilg H, Watson A, Wells JM. Intestinal permeability--a 
new target for disease prevention and therapy. BMC Gastroenterol 
2014; 14: 189 [PMID: 25407511 DOI: 10.1186/s12876-014-0189-7]
179 Santos J, Yang PC, Söderholm JD, Benjamin M, Perdue MH. Role 
of mast cells in chronic stress induced colonic epithelial barrier 
dysfunction in the rat. Gut 2001; 48: 630-636 [PMID: 11302959]
180 Söderholm JD, Yang PC, Ceponis P, Vohra A, Riddell R, 
Sherman PM, Perdue MH. Chronic stress induces mast cell-
dependent bacterial adherence and initiates mucosal inflammation 
in rat intestine. Gastroenterology 2002; 123: 1099-1108 [PMID: 
12360472]
181 McDermott JR, Bartram RE, Knight PA, Miller HR, Garrod DR, 
Grencis RK. Mast cells disrupt epithelial barrier function during 
enteric nematode infection. Proc Natl Acad Sci USA 2003; 100: 
7761-7766 [PMID: 12796512]
182 Zhou Q, Souba WW, Croce CM, Verne GN. MicroRNA-29a 
regulates intestinal membrane permeability in patients with irritable 
bowel syndrome. Gut 2010; 59: 775-784 [PMID: 19951903 DOI: 
10.1136/gut.2009.181834]
183 Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese 
R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche 
JP, Neunlist M. Impaired intestinal barrier integrity in the colon 
of patients with irritable bowel syndrome: involvement of soluble 
mediators. Gut 2009; 58: 196-201 [PMID: 18824556 DOI: 10.1136/
gut.2007.140806]
184 Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and 
hypersensitivity in the irritable bowel syndrome. Pain 2009; 146: 
41-46 [PMID: 19595511 DOI: 10.1016/j.pain.2009.06.017]
185 Shulman RJ, Eakin MN, Czyzewski DI, Jarrett M, Ou CN. 
Increased gastrointestinal permeability and gut inflammation 
in children with functional abdominal pain and irritable bowel 
syndrome. J Pediatr 2008; 153: 646-650 [PMID: 18538790 DOI: 
10.1016/j.jpeds.2008.04.062]
186 Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins 
AC, Spiller RC. Abnormal intestinal permeability in subgroups of 
diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 
2006; 101: 1288-1294 [PMID: 16771951]
187 Kerckhoffs AP, Akkermans LM, de Smet MB, Besselink MG, 
Hietbrink F, Bartelink IH, Busschers WB, Samsom M, Renooij W. 
Intestinal permeability in irritable bowel syndrome patients: effects 
of NSAIDs. Dig Dis Sci 2010; 55: 716-723 [PMID: 19255843 DOI: 
10.1007/s10620-009-0765-9]
188 Lee JW, Park JH, Park DI, Park JH, Kim HJ, Cho YK, Sohn 
CI, Jeon WK, Kim BI. Subjects with diarrhea-predominant IBS 
have increased rectal permeability responsive to tryptase. Dig 
Dis Sci 2010; 55: 2922-2928 [PMID: 20087660 DOI: 10.1007/
s10620-009-1094-8]
189 Bertiaux-Vandaële N, Youmba SB, Belmonte L, Lecleire S, 
Antonietti M, Gourcerol G, Leroi AM, Déchelotte P, Ménard JF, 
Ducrotté P, Coëffier M. The expression and the cellular distribution 
of the tight junction proteins are altered in irritable bowel syndrome 
patients with differences according to the disease subtype. Am 
J Gastroenterol 2011; 106: 2165-2173 [PMID: 22008894 DOI: 
10.1038/ajg.2011.257]
190 Bischoff SC. Food allergy and eosinophilic gastroenteritis and 
colitis. Curr Opin Allergy Clin Immunol 2010; 10: 238-245 [PMID: 
20431371 DOI: 10.1097/ACI.0b013e32833982c3]
191 Brown PM, Drossman DA, Wood AJ, Cline GA, Frazier KS, 
Jackson JI, Bronner J, Freiman J, Zambrowicz B, Sands A, Gershon 
MD. The tryptophan hydroxylase inhibitor LX1031 shows clinical 
benefit in patients with nonconstipating irritable bowel syndrome. 
Gastroenterology 2011; 141: 507-516 [PMID: 21684281 DOI: 
10.1053/j.gastro.2011.05.005]
192 Palsson OS, Morteau O, Bozymski EM, Woosley JT, Sartor RB, 
Davies MJ, Johnson DA, Turner MJ, Whitehead WE. Elevated 
vasoactive intestinal peptide concentrations in patients with irritable 
bowel syndrome. Dig Dis Sci 2004; 49: 1236-1243 [PMID: 
15387352]
193 Kerckhoffs AP, ter Linde JJ, Akkermans LM, Samsom M. SERT 
and TPH-1 mRNA expression are reduced in irritable bowel 
syndrome patients regardless of visceral sensitivity state in large 
intestine. Am J Physiol Gastrointest Liver Physiol 2012; 302: 
G1053-G1060 [PMID: 22323131 DOI: 10.1152/ajpgi.00153.2011]
194 Simrén M, Stotzer PO, Sjövall H, Abrahamsson H, Björnsson ES. 
Abnormal levels of neuropeptide Y and peptide YY in the colon in 
irritable bowel syndrome. Eur J Gastroenterol Hepatol 2003; 15: 
55-62 [PMID: 12544695]
195 Barbara G, Cremon C, De Giorgio R, Dothel G, Zecchi L, 
Bellacosa L, Carini G, Stanghellini V, Corinaldesi R. Mechanisms 
underlying visceral hypersensitivity in irritable bowel syndrome. 
Curr Gastroenterol Rep 2011; 13: 308-315 [PMID: 21537962 DOI: 
10.1007/s11894-011-0195-7]
196 van Wanrooij SJ, Wouters MM, Van Oudenhove L, Vanbrabant W, 
Mondelaers S, Kollmann P, Kreutz F, Schemann M, Boeckxstaens 
GE. Sensitivity testing in irritable bowel syndrome with rectal 
capsaicin stimulations: role of TRPV1 upregulation and sensitization 
in visceral hypersensitivity? Am J Gastroenterol 2014; 109: 99-109 
[PMID: 24189713 DOI: 10.1038/ajg.2013.371]
197 Willot S, Gauthier C, Patey N, Faure C. Nerve growth factor 
content is increased in the rectal mucosa of children with diarrhea-
predominant irritable bowel syndrome. Neurogastroenterol 
Motil 2012; 24: 734-739, e347 [PMID: 22625872 DOI: 10.1111/
j.1365-2982.2012.01933.x]
198 Barbara G, Gargano L, Cremon C, Vasina V, Dothel G, Carini G, 
De Giorgio R, Stanghellini V, Cogliandro R, Tonini M, De Ponti F, 
Corinaldesi R. Nerve growth and plasticity in the colonic mucosa of 
Sinagra E et al . Inflammation in IBS
2255 February 21, 2016|Volume 22|Issue 7|WJG|www.wjgnet.com
patients with irritable bowel syndrome. Gastroenterology 2010; 138: 
S65 [DOI: 10.1016/S0016-5085(10)60293-4]
199 Dothel G, Barbaro MR, Boudin H, Vasina V, Cremon C, Gargano 
L, Bellacosa L, De Giorgio R, Le Berre-Scoul C, Aubert P, Neunlist 
M, De Ponti F, Stanghellini V, Barbara G. Nerve fiber outgrowth is 
increased in the intestinal mucosa of patients with irritable bowel 
syndrome. Gastroenterology 2015; 148: 1002-1011.e4 [PMID: 
25655556 DOI: 10.1053/j.gastro.2015.01.042]
200 Gulbransen BD, Sharkey KA. Novel functional roles for enteric glia 
in the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 2012; 9: 
625-632 [PMID: 22890111 DOI: 10.1038/nrgastro.2012.138]
201 Andrews CN, Shaffer E, Ho W, Nasser Y, O’Hara JR, Sharkey KA. 
Enteric glia and enteroen-docrine cells in irritable bowel syndrome: 
controlled pilot study. Gastroenterology 2005; 128: A270
202 Barbara G, Cremon C, Annese V, Basilisco G, Bazzoli F, Bellini 
M, Benedetti A, Benini L, Bossa F, Buldrini P, Cicala M, Cuomo 
R, Germanà B, Molteni P, Neri M, Rodi M, Saggioro A, Scribano 
ML, Vecchi M, Zoli G, Corinaldesi R, Stanghellini V. Randomised 
controlled trial of mesalazine in IBS. Gut 2016; 65: 82-90 [PMID: 
25533646 DOI: 10.1136/gutjnl-2014-308188]
203 Barbara G, Cremon C, Carini G, Bellacosa L, Zecchi L, De Giorgio 
R, Corinaldesi R, Stanghellini V. The immune system in irritable 
bowel syndrome. J Neurogastroenterol Motil 2011; 17: 349-359 
[PMID: 22148103 DOI: 10.5056/jnm.2011.17.4.349]
204 Dunlop SP, Jenkins D, Neal KR, Naesdal J, Borgaonker M, Collins 
SM, Spiller RC. Randomized, double-blind, placebo-controlled trial 
of prednisolone in post-infectious irritable bowel syndrome. Aliment 
Pharmacol Ther 2003; 18: 77-84 [PMID: 12848628]
205 Barbara G, Stanghellini V, Cremon C, De Giorgio R, Fronzoni 
L, Serra M, Corinaldesi R. Aminosalicylates and other anti-
inflammatory compounds for irritable bowel syndrome. Dig Dis 
2009; 27 Suppl 1: 115-121 [PMID: 20203507 DOI: 10.1159/000268131]
206 Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, 
van der Heide S, Schemann M, Bischoff SC, van den Wijngaard 
RM, Boeckxstaens GE. The mast cell stabiliser ketotifen decreases 
visceral hypersensitivity and improves intestinal symptoms in 
patients with irritable bowel syndrome. Gut 2010; 59: 1213-1221 
[PMID: 20650926 DOI: 10.1136/gut.2010.213108]
207 Clarke G, Cryan JF, Dinan TG, Quigley EM. Review article: 
probiotics for the treatment of irritable bowel syndrome--focus on 
lactic acid bacteria. Aliment Pharmacol Ther 2012; 35: 403-413 
[PMID: 22225517 DOI: 10.1111/j.1365-2036.2011.04965.x]
208 Whelan K. Probiotics and prebiotics in the management of irritable 
bowel syndrome: a review of recent clinical trials and systematic 
reviews. Curr Opin Clin Nutr Metab Care 2011; 14: 581-587 [PMID: 
21892075 DOI: 10.1097/MCO.0b013e32834b8082]
209 DuPont AW, DuPont HL. The intestinal microbiota and chronic 
disorders of the gut. Nat Rev Gastroenterol Hepatol 2011; 8: 
523-531 [PMID: 21844910 DOI: 10.1038/nrgastro.2011.133]
210 Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of 
probiotics in the treatment of irritable bowel syndrome: a systematic 
review. Am J Gastroenterol 2009; 104: 1033-1049; quiz 1050 [PMID: 
19277023 DOI: 10.1038/ajg.2009.25]
211 Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, 
Glasziou P. A systematic review and meta-analysis: probiotics in the 
treatment of irritable bowel syndrome. BMC Gastroenterol 2009; 9: 
15 [PMID: 19220890 DOI: 10.1186/1471-230X-9-15]
212 Schmulson M, Chang L. Review article: the treatment of functional 
abdominal bloating and distension. Aliment Pharmacol Ther 2011; 33: 
1071-1086 [PMID: 21488913 DOI: 10.1111/j.1365-2036.2011.04637.x]
P- Reviewer: Jia HC    S- Editor: Yu J    L- Editor: Filipodia 
E- Editor: Wang CH 
Sinagra E et al . Inflammation in IBS
                                      © 2016 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc






I S S N  1 0  0 7  -   9  3 2  7
9    7 7 1 0  07   9 3 2 0 45
0  7
